Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study)

BACKGROUND: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has a potent inhibitory effect against both T790M resistance mutations and EGFR-TKI sensitizing in EGFR, with a relatively low affinity for wild-type EGFR. Osimertinib has been approved...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Transl Lung Cancer Res
Главные авторы: Chihara, Yusuke, Yamada, Tadaaki, Uchino, Junji, Tamiya, Nobuyo, Kaneko, Yoshiko, Kishimoto, Junji, Takayama, Koichi
Формат: Artigo
Язык:Inglês
Опубликовано: AME Publishing Company 2019
Предметы:
Study Protocol
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6976354/
https://ncbi.nlm.nih.gov/pubmed/32010586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2019.11.19
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы